Want to join the conversation?
Barry McCarver of Stephens asks about the new contracted revenue of $40MM under the fiber segment. $CSAL CEO Kenny Gunderman said some of this will actually be hitting the income statement this year and then there will be some in 2017 and 2018.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.